From: Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
Before PS matching | After PS matching | ||||
---|---|---|---|---|---|
Sitagliptin (N = 201,839) | Empagliflozin (N = 18,880) | Sitagliptin (N = 16,443) | Empagliflozin (N = 16,443) | ||
Diabetes medication | ⟶ PS matching | ||||
# antidiabetic drugs (mean) | 2.2 | 2.3 | 2.2 | 2.2 | |
Treatment naïve (%) | 13% | 7% | 8% | 8% | |
CV risk factors | |||||
Any CVD (%) | 37% | 24% | 25% | 25% | |
CAD (%) | 26% | 18% | 18% | 18% | |
Stroke (%) | 10% | 5% | 6% | 6% | |
PAD (%) | 10% | 5% | 5% | 5% | |
HF (%) | 11% | 5% | 5% | 5% | |
Lab results (not used for PS matching) | |||||
HbA1c (mean) | 8.3 | 8.5 | 8.6 | 8.5 |